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Abstract
Objective—We provide an update on medication use in infants admitted to the neonatal intensive
care unit (NICU) in the United States and examine how use has changed over time.
Study Design—We performed a retrospective review (2005–2010) of a large prospectively
collected administrative database.
Result—Medications most commonly administered during the study period were ampicillin,
gentamicin, caffeine citrate, vancomycin, beractant, furosemide, fentanyl, dopamine, midazolam,
and calfactant (56–681 exposures per 1000 infants). Those with the greatest relative increase in
use included azithromycin, sildenafil, and milrinone. Medications with the greatest relative
decrease in use included theophylline, metoclopramide, and doxapram.
Conclusion—Medication use in the NICU has changed substantially over time, and only 35% of
the most commonly prescribed medications are FDA-approved in infants.
Keywords
pharmacotherapy; trends over time
Introduction
Infants in the neonatal intensive care unit (NICU) are exposed to a large number of
medications, most of which are not labeled for use in infants because clinical trials for
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safety, dosing, and efficacy of drugs are lacking in this population.1 Hospitalized infants are
often excluded from clinical trials due to ethical concerns and difficulties with recruitment.2
Furthermore, these hospitalized infants in the NICU are more likely to be pre-term, with
greater proportions exhibiting renal and hepatic dysfunction. These characteristics are often
exclusion criteria for many clinical trials. As a result, clinicians are forced to prescribe
medications for purposes outside of their licensed indications (i.e., off-label use).3–5
Previous investigators described medication use in the NICU through 2005.6 However,
clinical practice and prescribing patterns change over time as clinical trial data and new
Food and Drug Administration (FDA) labeling information become available. The aims of
this study were (1) to provide the most recent description of current prescribing practices in
the NICU and (2) to examine changes in prescribing practices over time.
Methods
Study population
We obtained demographic, outcome, and medication administration data from infants
discharged from 305 NICUs managed by the Pediatrix Medical Group from 2005–2010.
Data were obtained from an administrative database that prospectively captures information
from daily progress notes generated by clinicians using a computer-assisted tool on all
infants cared for by the Pediatrix Medical Group. Information is collected regarding
maternal history and demographics, physical exam findings, medications, laboratory results,
culture results, diagnoses, and other aspects of clinical care. We excluded infants admitted
after day of life 120, and all vitamins (except vitamin A), nutritional supplements, vaccines,
eye drops, and topical medications.
Definitions
We used counts and proportions to describe medication use by 3 different methods. Total
medication courses (frequency or raw count) represented the number of times a unique
medication name was reported in the database. Exposure was defined as the number of
unique medication names that were reported for each patient. Days of use was defined as the
total number of days each medication was administered in the entire database. For example,
if a medication was prescribed to 2 patients once and to 1 patient twice for a duration of 2
days each time, the medication would be reported as: exposure=1+1+1=3; course=1+1+2=4;
days=(1*2)+(1*2)+(2*2)=8. In addition, medication exposures in extremely low birth
weight (ELBW, <1000 g birth weight) infants and in infants who died prior to NICU
discharge were determined.
The change in frequency of medication administration between 2005 and 2010 was
described by both absolute and relative change. Relative increases in medication use were
limited to medications with ≥1/1000 infant exposures in 2005, and relative decreases in
medication use were limited to medication with ≥1/1000 infant exposures in 2010. We
conducted the analysis using STATA 12 (College Station, TX). This study was approved by
the Duke Institutional Review Board.
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Study population and counting method
A total of 450,386 infants were discharged during the study period, and 29,336 (6.5%) were
ELBW infants. The median birth weight of the study population was 2490 g (25th, 75th
percentile: 1830, 3191), and the median gestational age was 35 weeks (33, 38). The median
length of hospitalization was 10 days (5, 21), and 56% of the infants were male. Overall
mortality was 2.4%, which was similar to the previous study (2.7%).
We identified 1,655,397 unique medication courses for 229 medications. The mean number
of medication courses per infant was 4 (1, 14) for the entire cohort and 17 (2, 45) for ELBW
infants. There were minimal differences in the rankings of medications when calculated by
the 3 methods. Therefore, only exposures were reported for Tables 2 through 6. The 10 most
commonly reported medications, by exposure, in the NICU were ampicillin, gentamicin,
caffeine citrate, vancomycin, beractant, furosemide, fentanyl, dopamine, midazolam, and
calfactant (Table 1). For ELBW infants, the 10 most commonly reported medications by
exposure were gentamicin, ampicillin, caffeine citrate, vancomycin, furosemide, dopamine,
beractant, indomethacin, fentanyl, and albuterol (Table 2). FDA approval status for the
medications most commonly used in the ELBW population is also shown in Table 2.
Medication use between 2005 and 2010
Drugs with the greatest relative increase in medication exposure from 2005 to 2010 included
azithromycin, sildenafil, milrinone, ibuprofen, linezolid, cefoxitin, methadone, vitamin A,
hyaluronidase, and poractant alpha (Table 3). Those with the greatest absolute increase in
medication exposure from 2005 to 2010 included poractant alpha, vitamin A, ibuprofen,
fluconazole, piperacillin/tazobactam, lansoprazole, methadone, morphine, meropenem, and
nitric oxide (Table 4). Medications appearing on both lists included ibuprofen, methadone,
and vitamin A.
Medication decreases between 2005 and 2010
Drugs with the greatest relative decrease in medication exposure from 2005 to 2010
included theophylline, metoclopramide, doxapram, aminophylline, epoietin alpha, imipenem
+cilastatin, ranitidine, sodium polystyrene sulfonate, and bethanechol (Table 5). Those with
the greatest absolute decrease in medication exposure from 2005 to 2010 included
metoclopramide, ranitidine, ampicillin, cefotaxime, indomethacin, epoietin alpha, beractant,
gentamicin, dopamine, and calfactant (Table 6). Medication use in ELBW infants is shown
in Tables 7–10.
Discussion
Of the most commonly reported medications identified in our study, only 35% are FDA-
approved in the newborn. From 1997–2010, 28 drugs had 24 FDA labeling changes in
neonates. Only 2, famotidine and linezolid, were among the top 100 medications (#62 and
#100, respectively). Such off-label drug use is concerning because, frequently, little is
known about the drugs’ potential side effects and adverse events; furthermore, dangerous
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errors may be made in adjusting adult doses and formulations for infants and children. In
fact, off-label drug use is associated with increased adverse drug reactions,7 and the
incidence of death and injury associated with adverse drug events in infants and children is
likely substantially higher than what is actually reported.8
Several factors may have influenced the changes in medication use observed over time. An
increasing number of studies investigating safety and pharmacokinetic properties of specific
molecules have led to a better understanding of their effects in the target population. For
example, emerging evidence has demonstrated the effectiveness of fluconazole prophylaxis
in preventing invasive Candida infection in ELBW infants at high risk of invasive
candidiasis.9–11 In addition, the dosing of fluconazole has been described for both treatment
and prophylaxis.12 This increased understanding of the dosing, safety, and efficacy around
fluconazole use likely accounts for the increase in its use (ranked 4th in absolute increase
and 18th in relative increase).
On the other hand, little evidence exists for the efficacy of metoclopramide use for
gastroesophageal reflux disease (GERD) in infants, which showed the second largest
relative decrease in use between 2005 and 2010. A 2006 systematic literature review of
metoclopramide for GERD in infants aged 0 to 23 months identified 4 studies that reported
adverse effects of therapy, including irritability, dystonic reactions, drowsiness, oculogyric
crisis, emesis, and apnea.13 In 2009, the FDA required manufacturers to add a box warning
to their drug labels about the risk of metoclopramide’s long-term or high-dose use: chronic
use of metoclopramide has been linked to tardive dyskinesia even after therapy has been
discontinued.14 During the time period of our study, Pediatrix Medical Group implemented
a new electronic module dedicated to clinical quality improvement initiatives,15 the success
of which can be observed with the decrease in anti-reflux medication use.16 Even with the
decrease in metoclopramide use, however, metoclopramide was one top 20 most commonly
used medications in the NICU.
Similarly, although ranitidine remained in the top 15 most commonly used medications in
both the NICU, it experienced the second largest absolute decrease in medication use from
2005 to 2010. During this time, data were published linking the use of H2 blockers to
necrotizing enterocolitis (NEC) in very low birth weight (<1500 g birth weight) infants
(odds ratio = 1.71 [95% confidence interval: 1.34–2.19]).17
In addition, medications that have increased in use may have their own risks and adverse
effects. There has been a decrease in third-generation cephalosporin use after their use was
associated with increased risk of Candida infections.18 This decrease corresponded with an
increased use of piperacillin-tazobactam (ranked 5th in absolute increase and 14th in relative
increase) and meropenem (ranked 9th in absolute increase and 13th in relative increase).
These agents may carry similar risks given their broad spectrum of antimicrobial activity.
The introduction of newer and potentially safer medications may also drive changes in
medication use. For example, indomethacin has been the conventional treatment for patent
ductus arteriosus (PDA) in premature infants. In April 2006, the FDA approved ibuprofen
lysine for closure of clinically significant PDA in premature infants because studies have
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shown ibuprofen to be safer and equally as effective as indomethacin.19 Subsequently, there
has been a rise in the use of ibuprofen (3rd largest absolute increase in medication use) and a
fall in indomethacin use (5th largest absolute decrease in medication use). However, in spite
of these changes in prescribing patterns, indomethacin is still a commonly used medication
in the ELBW infants (ranked 8th).
One of the most common complications of premature birth is bronchopulmonary dysplasia
(BPD),20 and up to 20% of infants with BPD develop pulmonary hypertension. As a result,
sildenafil, approved for pulmonary hypertension in adults, has increased in use since 2005
(2nd greatest relative increase). However, the FDA recently recommended against the use of
sildenafil in children ages 1 though 17 for the treatment of pulmonary arterial hypertension.
This recommendation was based on a recent long-term pediatric clinical trial showing that
children taking a high dose of sildenafil had a higher risk of death when compared to
children taking a low dose, and that the low dose of sildenafil was not effective in improving
exercise ability.21
The strengths of our study include the use of a large, representative cohort, as well as daily
documentation of medication prescriptions for infants in the NICU. Our study is limited by
the use of administrative data for the analysis. These data are not from a prospective clinical
trial that has undergone the scrutiny of independent monitoring, but rather are derived from
prospectively collected electronic documentation.
In summary, we identified the most commonly reported medications used in the NICU and
how medication use has changed over time. Frequent studies of medication use patterns
should be conducted to facilitate optimal prioritization of drug studies in infants. As many of
the drugs used in the NICU are used off-label and have not been adequately studied in this
population, these data are useful for researchers and NIH in setting research priorities.
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Table 1
Medications most commonly used in the NICU
Rank Medication Exposure* Courses* Days of use*
1 Ampicillin 681 709 3069
2 Gentamicin 676 785 3521
3 Caffeine citrate 156 199 3908
4 Vancomycin 91 150 987
5 Beractant 82 91 103
6 Furosemide 81 171 668
7 Fentanyl 70 86 677
8 Dopamine 62 77 327
9 Midazolam 61 71 679
10 Calfactant 56 66 72
11 Metoclopramide 54 63 706
12 Ranitidine 52 62 591
13 Poractant alpha 51 56 61
14 Morphine 51 62 527
15 Cefotaxime 43 53 316
16 Acetaminophen 43 48 241
17 Indomethacin 39 50 121
18 Phenobarbital 38 48 427
19 Albuterol 27 35 611
20 Epoietin alpha 26 30 631
21 Lorazepam 25 28 290
22 Hydrocortisone 25 32 290
23 Tobramycin 24 34 189
24 Erythromycin 24 25 103
25 Dobutamine 20 23 78
26 Dexamethasone 20 30 159
27 Fluconazole 19 23 321
28 Clindamycin 17 19 128
29 Palivizumab 17 17 24
30 Acyclovir 16 16 82
31 Vitamin A 15 15 363
32 Insulin 14 17 73
33 Ursodeoxycholic acid 14 18 259
34 Lansoprazole 14 15 106
35 Spironolactone 14 17 251
36 Chlorothiazide 12 16 230
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Rank Medication Exposure* Courses* Days of use*
37 Aminophylline 12 13 165
38 Ceftazidime 12 15 99
39 Alprostadil 12 12 22
40 Nitric oxide 11 12 82
41 Piperacillin/tazobactam 11 15 115
42 Epinephrine 11 12 25
43 Amoxicillin 11 12 72
44 Metronidazole 11 13 97
45 Oxacillin 10 14 67
46 Nafcillin 9.0 11 66
47 Amphotericin B products 8.9 11 99
48 Amikacin 8.8 12 77
49 Vecuronium 8.5 9.8 33
50 Ibuprofen 8.3 11 35
51 Cefazolin 7.5 8.1 27
52 Meropenem 7.0 8.9 82
53 Simethicone 6.9 7.2 59
54 Levothyroxine 6.7 7.2 157
55 Fluticasone 6.7 8.1 170
56 Budesonide 6.6 7.6 153
57 Phenylephrine 6.6 7.3 29
58 Omeprazole 6.5 7.0 64
59 Epinephrine racemic 6.3 7.4 20
60 Cefepime 6.1 7.7 58
61 Pancuronium 6.1 6.8 22
62 Famotidine 5.3 6.2 62
63 Methadone 5.2 6.1 86
64 Digoxin 5.1 5.7 28
65 Chloral hydrate 5.0 5.5 28
66 Penicillin G 4.7 4.9 38
67 Naloxone 4.3 4.4 4.7
68 Pentobarbital 4.3 4.7 49
69 Prednisone/prednisolone 4.2 5.2 47
70 Aluminum/magnesium hydroxide 4.2 4.7 27
71 Theophylline 4.1 5.0 102
72 Filgrastim 3.8 4.4 13
73 Hydrochlorothiazide 3.7 4.5 61
74 Rifampin 3.6 3.8 36
75 Propranolol 3.4 3.7 15
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Rank Medication Exposure* Courses* Days of use*
76 THAM acetate 3.1 4.0 5.2
77 Imipenem+cilastatin 3.0 3.3 29
78 Milrinone 2.9 3.0 15
79 Hyaluronidase 2.8 2.9 3.1
80 Bumetanide 2.8 3.8 26
81 Hydralazine 2.5 2.8 28
82 Surfactant (unknown type) 2.4 2.6 3.9
83 Captopril 2.3 2.6 24
84 Beclomethasone 2.1 2.8 32
85 Adenosine 2.1 2.5 4.0
86 Acetazolamide 2.1 3.7 24
87 Sodium polystyrene sulfonate 2.1 2.3 5.3
88 Diazepam 2.0 2.4 28
89 Zidovudine 1.9 2.0 15
90 Cephalexin 1.9 2.0 9.5
91 Ceftriaxone 1.8 1.8 5.7
92 Ipratropium 1.7 1.9 42
93 Dornase Alpha 1.6 2.2 16
94 Sulfamethoxazole+trimethoprim 1.6 1.8 16
95 Enalapril 1.5 1.8 13
96 Cefoxitin 1.5 1.6 4.9
97 Doxapram 1.4 2.0 25
98 Fosphenytoin 1.4 1.6 10
99 Sildenafil 1.4 1.6 27
100 Linezolid 1.3 1.6 14
*
Units for courses, exposure, and days of use, per 1000 infants.
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Table 2
Medications most commonly used in extremely low birth weight infants
Rank Medication Exposure* FDA-approved in ELBW infants
1 Gentamicin 896 Yes
2 Ampicillin 881 No
3 Caffeine citrate 704 No
4 Vancomycin 559 Yes
5 Furosemide 495 No
6 Dopamine 425 No
7 Beractant 339 Yes
8 Indomethacin 334 Yes
9 Fentanyl 322 No
10 Albuterol 241 No
11 Calfactant 240 Yes
12 Midazolam 236 Yes
13 Hydrocortisone 215 No
14 Cefotaxime 214 Yes
15 Ranitidine 212 No
16 Metoclopramide 195 No
17 Morphine 194 No
18 Fluconazole 191 No
19 Dexamethasone 176 No
20 Vitamin A 174 No
*
Per 1000 infants.
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Table 3
Greatest relative increase in exposure between 2005 and 2010 (≥1/1000 infant exposures in 2010)
Rank Medication % Change Exposure (2005)* Exposure (2010)*
1 Azithromycin 2900 0.1 3.0
2 Sildenafil 1050 0.2 2.3
3 Milrinone 900 0.4 4.0
4 Ibuprofen 650 1.4 11
5 Linezolid 500 0.4 2.4
6 Cefoxitin 350 0.4 1.8
7 Methadone 158 3.1 8.0
8 Vitamin A 152 8.3 21
9 Hyaluronidase 107 1.5 3.1
10 Poractant alpha 101 32 63
11 Meropenem 100 4.5 9.0
12 Piperacillin/tazobactam 97 6.2 12
13 Cefepime 70 4.6 7.8
14 Famotidine 60 4.7 7.5
15 Lansoprazole 58 9.8 16
16 Fluconazole 44 14 21
17 Diazepam 44 1.6 2.3
18 Nitric oxide 42 8.9 13
19 Cefazolin 38 6.3 8.7
20 Prednisone/Prednisolone 36 3.9 5.3
*
Per 1000 infants.
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Table 4
Greatest absolute increase in exposure between 2005 and 2010
Rank Medication Exposure increase* Exposure in 2005* Exposure in 2010*
1 Poractant alpha 32 32 63
2 Vitamin A 13 8.3 21
3 Ibuprofen 9.1 1.4 11
4 Fluconazole 6.4 14 21
5 Piperacillin/tazobactam 6.0 6.2 12
6 Lansoprazole 5.7 9.8 16
7 Methadone 4.9 3.1 8.0
8 Morphine 4.8 49 54
9 Meropenem 4.5 4.5 9.0
10 Nitric oxide 3.7 8.9 13
11 Milrinone 3.6 0.4 4.0
12 Cefepime 3.2 4.6 7.8
13 Lorazepam 3.0 23 26
14 Azithromycin 2.9 0.1 3.0
15 Metronidazole 2.9 8.4 11
16 Famotidine 2.8 4.7 7.5
17 Acyclovir 2.4 16 18
18 Cefazolin 2.4 6.3 8.7
19 Sildenafil 2.1 0.2 2.3
20 Linezolid 2.0 0.4 2.4
*
Per 1000 infants.
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Table 5
Greatest relative decrease in exposure between 2005 and 2010 (≥1/1000 infant exposures in 2005)
Rank Medication % Change Exposure (2005)* Exposure (2010)*
1 Theophylline −84 6.9 1.1
2 Metoclopramide −84 88 14
3 Doxapram −74 2.3 0.6
4 Aminophylline −73 20 5.4
5 Epoietin alpha −66 42 15
6 Imipenem+cilastatin −63 4.8 1.8
7 Ranitidine −61 80 31
8 Sodium polystyrene sulfonate −61 3.1 1.2
9 Bethanechol −59 2.2 0.9
10 Indomethacin −58 61 26
11 Cefotaxime −56 67 29
12 Amphotericin B products −53 12 5.5
13 Ipratropium −52 2.7 1.3
14 Ceftazidime −51 17 8.5
15 Acetylcysteine −47 1.7 0.9
16 Oxacillin −46 12 6.4
17 Dobutamine −46 26 14
18 Ceftriaxone −46 2.4 1.3
19 Rifampin −45 4.2 2.3
20 Palivizumab −42 20.5 11.9
*
Per 1000 infants.
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Table 6
Greatest absolute decrease in exposure between 2005 and 2010
Rank Medication Decrease in exposure* Exposure in 2005* Exposure in 2010*
1 Metoclopramide −74 88 14
2 Ranitidine −49 80 31
3 Ampicillin −39 699 659
4 Cefotaxime −38 67 29
5 Indomethacin −35 61 26
6 Epoietin alpha −28 42 15
7 Beractant −26 93 67
8 Gentamicin −26 684 658
9 Dopamine −23 73 50
10 Calfactant −20 67 47
11 Vancomycin −17 96 79
12 Furosemide −16 89 73
13 Aminophylline −15 20 5.4
14 Albuterol −12 34 22
15 Dobutamine −12 26 14
16 Midazolam −9.3 63 54
17 Ceftazidime −8.7 17 8.5
18 Palivizumab −8.6 21 12
19 Spironolactone −6.4 17 11
20 Amphotericin B products −6.3 12 5.5
*
Per 1000 infants.
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Table 7
Greatest relative increase in exposure between 2005 and 2010 in ELBW infants (≥1/1000 infant exposures in
2010)
Rank Medication % Change Exposure (2005)* Exposure (2010)*
1 Azithromycin 2050 0.4 8.6
2 Ibuprofen 1340 7.8 112
3 Sildenafil 1125 1.6 20
4 Carnitine 733 3.6 30
5 Cefuroxime 700 0.2 1.6
6 Milrinone 525 1.6 10
7 Linezolid 464 3.1 18
8 Amlodipine 291 1.1 4.3
9 Ganciclovir 236 1.1 3.7
10 Cefoxitin 219 2.7 8.6
*
Per 1000 infants.
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Table 8
Greatest absolute increase in exposure between 2005 and 2010 in ELBW infants
Rank Medication Exposure increase* Exposure in 2005* Exposure in 2010*
1 Vitamin A 179 93 273
2 Caffeine citrate 176 620 796
3 Poractant alpha 135 100 235
4 Ibuprofen 105 7.8 112
5 Fluconazole 95 141 236
6 Gentamicin 67 853 920
7 Fentanyl 47 295 342
8 Meropenem 45 36 81
9 Piperacillin/Tazobactam 44 45 89
10 Lorazepam 38 76 114
*
Per 1000 infants.
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Table 9
Greatest relative decrease in exposure between 2005 and 2010 in ELBW infants (≥1/1000 infant exposures in
2005)
Rank Medication % Change Exposure (2005)* Exposure (2010)*
1 Cromolyn −93 2.7 0.2
2 Terbutaline −88 3.4 0.4
3 Scopolamine −87 4.5 0.6
4 Norepinephrine −85 1.3 0.2
5 Metoclopramide −79 298 62
6 Ceftizoxime −75 1.6 0.4
7 Aztreonam −74 3.8 1.0
8 Theophylline −73 38 10
9 Doxapram −70 22 6.7
10 Chlorpromazine −69 1.3 0.4
*
Per 1000 infants.
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Table 10
Greatest absolute decrease in exposure between 2005 and 2010 in ELBW infants
Rank Medication Decrease in exposure* Exposure in 2005* Exposure in 2010*
1 Metoclopramide −236 298 62
2 Ranitidine −152 293 141
3 Epoietin alpha −143 223 81
4 Indomethacin −139 424 285
5 Cefotaxime −118 282 164
6 Aminophylline −64 94 30
7 Albuterol −60 283 223
8 Dopamine −57 449 392
9 Ceftazidime −55 130 84
10 Dobutamine −51 162 110
*
Per 1000 infants.
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